Acurx announces results of its pioneering research with ibezapolstat in collaboration with leiden university medical center at the premier international c. difficile symposium

Results feature high-resolution elucidation of interaction of ibezapolstat with its molecular target mechanistic findings explain ibezapolstat's properties of lacking cross resistance with other antibiotics and not fostering the emergence of enterococcus, including vancomycin-resistant strains, a unique differentiation among anti-cdi antibiotics molecular structure data will be used to guide rational design of new systemic therapeutic compounds with improved inhibitory activity and pk characteristics planning continues to prepare to advance ibezapolstat into international phase 3 clinical trials for treatment of c. difficile infection (cdi) acurx is also preparing requests for regulatory guidance to initiate clinical trials in the european union, the united kingdom, japan and canada ibezapolstat has previously received fda qidp and fast-track designation from fda staten island, n.y.
ACXP Ratings Summary
ACXP Quant Ranking